Altered expression of a metformin-mediated radiation response in SA-NH and FSa tumor cells treated under in vitro and in vivo growth conditions

References

• Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli L, Birman E, Viollet B, Ferbeyre G, Pollak MN. 2012. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res. 5:536–543.
   PubMed Web of Science ®Google Scholar
• Andrzejewski S, Gravel S-P, Pollak M, St-Pierre J. 2014. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metabol. 2:1–14.
   PubMedGoogle Scholar
• Bellazzo A, Di Minin G, Collavin L. 2015. Cytoplasmic gain-of-function mutant p53 contributes to inflammation-associated cancer. Molec Cell Oncol. 2:e1002719-1-e1002719-3.
   Google Scholar
• Bost F, Ben-Sahra I, Tanti J-F. 2012. Prevention of mutagenesis: new potential mechanisms of metformin action in neoplastic cells. Cancer Prev Res. 5:503–506.
   PubMed Web of Science ®Google Scholar
• Boudreau HE, Casterline BW, Burke DJ, Leto TL. 2014. Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells. Brit J Cancer. 110:2569–2582.
   PubMed Web of Science ®Google Scholar
• Budanov AV. 2014. The role of tumor suppressor p53 in the antioxidant defense and metabolism. Subcell Biochem. 86:337–358.
   Google Scholar
• Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. 2007. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cells growth. Cancer Res. 67:6745–6752.
   PubMed Web of Science ®Google Scholar
• Cheng G, Lanza-Jacoby S. 2015. Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: role of NOX4. Biochem Biophys Res Comm. 465:41–46.
   PubMed Web of Science ®Google Scholar
• Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ, Johnson BD, Hardy M, et al. 2016. Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer Res. 76:3904–3915.
   PubMed Web of Science ®Google Scholar
• Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rozenfeld N, et al. 2013. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 23:634–646.
   PubMed Web of Science ®Google Scholar
• Goncalves AP, Maximo V, Lima J, Singh KK, Soares P, Videira A. 2011. Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. Biochim et Biophys Acta. 1813:492–499.
   PubMed Web of Science ®Google Scholar
• Green ML, Singh AV, Ruest LB, Pisano MM, Prough RA, Knudsen TB. 2011. Differential programming of p53-deficient embryonic cells during rotenone block. Toxicol. 290:31–41.
   PubMed Web of Science ®Google Scholar
• Khouri H, Collin F, Bonnefont-Rousselot D, Legrand A, Jore D, Gardes-Albert M. 2004. Radical-induced oxidation of metformin. Eur J Biochem. 271:4745–4752.
   PubMedGoogle Scholar
• Koritzinsky M. 2015. Metformin: a novel biological modifier of tumor response to radiation therapy. Int J Radiat Oncol Biol Phys. 93:454–464.
   PubMed Web of Science ®Google Scholar
• Kramer CY. 1956. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics. 12:309–310.
   Web of Science ®Google Scholar
• Matoba S, Kang J-G, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. 2006. p53 regulates mitochondrial respiration. Science. 312:1650–1653.
   PubMed Web of Science ®Google Scholar
• Milicevic Z, Kasapovic J, Gavrilovic L, Milovanovic Z, Bajic V, Spremo-Potparevic B. 2014. Mutant p53 expression and antioxidant status deficiency in breast cancer. EXCLI J. 13:691–708.
   PubMed Web of Science ®Google Scholar
• Miller RC, Murley JS, Grdina DJ. 2014. Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs. Radiat Res. 181:464–470.
   PubMed Web of Science ®Google Scholar
• Miller RC, Murley JS, Rademaker AW, Woloschak GE, Li JJ, Weichselbaum RR, Grdina DJ. 2016. Very low doses of ionizing radiation and redox associated modifiers affect survivin-associated changes in radiation sensitivity. Free Radic Biol Med. 99:110–119.
   PubMed Web of Science ®Google Scholar
• Muaddi H, Chowdhury S, Vellanki R, Zamiara P, Koritzinsky M. 2013. Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol. 108:446–450.
   PubMed Web of Science ®Google Scholar
• Murley JS, Kataoka Y, Cao D, Li JJ, Oberley LW, Grdina DJ. 2004. Delayed radioprotection by NFκB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs. Radiat Res. 162:536–546.
   PubMed Web of Science ®Google Scholar
• Pervin S, Tran L, Urman R, Braga M, Parveen M, Li SA, Chaudhuri G, Singh R. 2013. Oxidative stress specifically downregulates survivin to promote breast tumour formation. Brit J Cancer. 108:848–858.
   PubMed Web of Science ®Google Scholar
• Picone P, Nuzzo D, Caruana L, Messina E, Barera A, Vasto S, Di Carlo M. 2015. Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: use of insulin to attenuate metformin’s effect. Biochim et Biophys Acta. 1853:1046–1059.
   PubMed Web of Science ®Google Scholar
• Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov, PM. 2005. The antioxidant function of the p53 tumor suppressor. Nature Medicine. 11:1306–1313.
   PubMed Web of Science ®Google Scholar
• Schimming R, Mason KA, Hunter N, Weil M, Kishi K, Milas L. 1999. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chermother Pharm. 43:165–172.
   PubMed Web of Science ®Google Scholar
• Schockel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, Algire C, Hägebarth A, Willems PH, Kopitz C, et al. 2015. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metabol. 3:1–16.
   PubMedGoogle Scholar
• Sinthupibulyakit C, Ittarat W, St. Clair WH, St. Clair DK. 2010. p53 protects lung cancer cells against metabolic stress. Int J Oncol. 37:1575–1581.
   PubMed Web of Science ®Google Scholar
• Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, et al. 2013. Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2:99–107.
   PubMed Web of Science ®Google Scholar
• Solaini G, Sgarbi G, Baracca A. 2011. Oxidative phosphorylation in cancer cells. Biochimica Biophysica Acta. 1807:534–542.
   PubMed Web of Science ®Google Scholar
• Song CW, Lee H, Dings RPM, Williams B, Powers J, Dos Santos T, Choi BH, Park HJ. 2012. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 362:1–7.
   Google Scholar
• Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. 2007. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 27:591–608.
   PubMed Web of Science ®Google Scholar
• Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G, Tsakiridis T. 2013. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 108:2021–2032.
   PubMed Web of Science ®Google Scholar
• Sui X, Xu Y, Wang X, Han W, Pan H, Xiao M. 2015. Metformin: a novel but controversial drug in cancer prevention and treatment. Mol Pharm. 12:3783–3791.
   PubMed Web of Science ®Google Scholar
• Turrens JF. 2003. Mitochondrial formation of reactive oxygen species. J Physiol. 552:335–344.
   PubMed Web of Science ®Google Scholar
• Weinberg SE, Chandel NS. 2015. Targeting mitochondria metabolism for cancer therapy. Nature Chem Biol. 11:9–15.
   PubMed Web of Science ®Google Scholar
• Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu G, Budinger SGR, Chandel NS. 2014. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2242:1–18.
   Google Scholar
• Zannella V, Dal Pra A, Muaddi H, McKee T, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P, Milosevic M, et al. 2013. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res. 19:5741–5750.
   Web of Science ®Google Scholar
• Zhang T, Zhang L, Zhang T, Fan J, Wu K, Guan Z, Wang X, Li L, Hsieh JT, He D, Guo P. 2014. Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKcs in vitro and in vivo. Radiat Res. 181:641–649.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Storr SJ, Johnson K, Green AR, Rakha EA, Ellis IO, Morgan DAL, Martin SG. 2014. Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget. 5:12936–12949.
   PubMed Web of Science ®Google Scholar
• Zhou S, Kachhap S, Singh KK. 2003. Mitochondrial impairment in p53-deficient human cancer cells. Mutagenesis. 18:287–289.
   PubMed Web of Science ®Google Scholar